Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1/2 1Phase 1 1

Status

Completed 3

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 32Genitourinary 15Gastrointestinal 9Other hematologic neoplasm 6Lymphoid 6Plasma cell 4Sarcoma 3Breast 3NET 2Endocrine 2Tumor-Agnostic 1Thoracic 1Gynecologic 1CNS 1

Conditions

Triple Negative Breast Neoplasms 2Breast Neoplasms 2Breast Carcinoma In Situ 1

Interventions

Trastuzumab 692Paclitaxel 678Cyclophosphamide 634Docetaxel 553Capecitabine 467Letrozole 407Carboplatin 392Fulvestrant 377Doxorubicin 330Tamoxifen 288pembrolizumab 270Anastrozole 252Epirubicin 249exemestane 238pertuzumab 226Bevacizumab 214Radiotherapy 213Gemcitabine 211Vinorelbine 188palbociclib 183Lapatinib 175130-nm albumin-bound paclitaxel 168Albumin-Bound Paclitaxel 156Exercise 147Magnetic Resonance Spectroscopy 145eribulin 144Taxes 134Fluorouracil 131Everolimus 118Cisplatin 117

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Introns × Breast × Clear all
NCT04081389 2023-09-11

Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer

Roswell Park Cancer Institute

Phase 1 Completed
9 enrolled 17 charts
Breast

Breast Carcinoma In Situ, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03599453 2023-07-18

Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer

Roswell Park Cancer Institute

Phase EARLY_PHASE1 Completed
8 enrolled
Breast

Triple Negative Breast Neoplasms

NCT03066947 2021-01-29

SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer

BriaCell Therapeutics Corporation

Phase 1/2 Completed
24 enrolled 12 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡